On Sunday, Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma ...
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Arcellx Inc (Symbol: ACLX) entered into oversold territory, hitting an RSI reading of 27.7 ...
Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of ...
In trading on Friday, shares of Arcellx Inc (Symbol: ACLX) crossed below their 200 day moving average of $69.38, changing hands as low as $67.43 per share. Arcellx Inc shares are currently trading ...
REDWOOD CITY, Calif., December 09, 2024--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback